Log in

NASDAQ:VXRT - Vaxart Stock Price, Forecast & News

$1.09
+0.05 (+4.81 %)
(As of 02/21/2020 03:55 AM ET)
Today's Range
$1.01
Now: $1.09
$1.10
50-Day Range
$0.34
MA: $0.74
$1.59
52-Week Range
$0.25
Now: $1.09
$5.00
Volume2.55 million shs
Average Volume10.62 million shs
Market Capitalization$52.02 million
P/E RatioN/A
Dividend YieldN/A
Beta0.31
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
Phone650-550-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 million
Book Value$1.57 per share

Profitability

Net Income$-18,000,000.00
Net Margins-222.20%

Miscellaneous

Employees34
Market Cap$52.02 million
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.


Vaxart (NASDAQ:VXRT) Frequently Asked Questions

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

How were Vaxart's earnings last quarter?

Vaxart Inc (NASDAQ:VXRT) released its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.04. The biotechnology company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.44 million. Vaxart had a negative return on equity of 115.71% and a negative net margin of 222.20%. View Vaxart's Earnings History.

When is Vaxart's next earnings date?

Vaxart is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Vaxart.

What price target have analysts set for VXRT?

2 analysts have issued 12-month target prices for Vaxart's shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Vaxart's stock price to reach $4.00 in the next year. This suggests a possible upside of 267.0% from the stock's current price. View Analyst Price Targets for Vaxart.

What is the consensus analysts' recommendation for Vaxart?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaxart.

Has Vaxart been receiving favorable news coverage?

News coverage about VXRT stock has been trending somewhat positive this week, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaxart earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Vaxart.

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

Who are Vaxart's key executives?

Vaxart's management team includes the folowing people:
  • Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)
  • Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)
  • Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)
  • Mr. Brant Biehn, Sr. VP of Commercial Operations

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.87%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker and Wouter Latour. View Institutional Ownership Trends for Vaxart.

Which major investors are buying Vaxart stock?

VXRT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker and Wouter Latour. View Insider Buying and Selling for Vaxart.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $1.09.

How big of a company is Vaxart?

Vaxart has a market capitalization of $52.02 million and generates $4.16 million in revenue each year. The biotechnology company earns $-18,000,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Vaxart employs 34 workers across the globe.View Additional Information About Vaxart.

What is Vaxart's official website?

The official website for Vaxart is http://www.vaxart.com/.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]


MarketBeat Community Rating for Vaxart (NASDAQ VXRT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel